AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
There’s a party going on at DISCO Pharma’s European headquarters after the precision medicine biotech signed its second major pharma partnership of the year—first Amgen, now AbbVie.
comments(0)
5-min edit window · permanent after that